...
首页> 外文期刊>Therapeutic Drug Monitoring >Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases
【24h】

Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases

机译:生物制药:参考产品和生物仿制性治疗炎症性疾病

获取原文
获取原文并翻译 | 示例
           

摘要

Biopharmaceuticals are primarily therapeutic proteins developed to perform specific functions by acting on the disease pathophysiology. Compared with low-molecular chemically synthesized drugs, production of biopharmaceuticals is much more complex and routes of administration and pharmacokinetics differ. Biopharmaceuticals are blockbusters in the treatment of inflammatory diseases, such as psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases, and the introduction of these drugs has revolutionized treatment. Disadvantages include their high costs and the fact that they can evoke antidrug antibodies leading to decreased efficacy. Treatment can be optimized through the development of dosing algorithms and cost can be reduced by biosimilars, after a comparable biological activity, safety, and efficacy have been demonstrated.
机译:生物制药主要是通过作用于疾病病理生理学进行特定功能的治疗性蛋白质。 与低分子化学合成药物相比,生物制药的生产更复杂,给药途径和药代动力学不同。 生物制药是治疗炎症性疾病的肿块,如牛皮癣,多发性硬化症,风湿病和炎症性肠病,以及这些药物的引入已经彻底改变了治疗。 缺点包括它们的高成本和它们可以让抗皱抗体引起疗效降低的事实。 可以通过发育给药算法的发育优化治疗,并且通过生物仿制性可以减少成本,经过可比的生物活性,安全性和功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号